We support boolean queries, use +,-,<,>,~,* to alter the weighting of terms
THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 28,2023. Software application which can analyze basic Western blot data and export them for use in spreadsheet programs. Users can create standardized or custom lab reports and can share them with colleagues. Image Studio Lite has been discontinued and replaced with Empiria Studio Software.
The Osteoarthritis Biomarkers Project (OABP) is a consortium designed to identify and classify biological markers of progression of knee osteoarthritis. Their goal is to advance the ability to predict the individual risk of developing severe OA and to monitor progression of OA.
The OPTObacteria consortium aims to develop a multianalyte and automatic laboratory detector (ALD) for antibiotic resistant infections. The goal is to detect these analytes within 4-6 hours from the sample collection, providing a report with the actual patient status, and predicting emerging drug resistance through the companion epidemiology software. The platform technology for this consortium is an opto electronic device, in which the appropriate ligand-probe, linked onto an opto electronic surface, will be able of specifically recognize biomolecules of the resistant infections.
The Multiple Sclerosis Outcome Assessments Consortium (MSOAC) is a public-private partnership which aims to accelerate the development of new therapies for MS by generating new tools for measuring outcomes in clinical trials. It is collecting, standardizing, and analyzing data about MS with the goal of qualifying new measures of disability for the disease. MSOAC is the newest of the eight consortia of Critical Path Institute (C-Path), a nonprofit organization that is dedicated to accelerating drug development by delivering on the mission outlined by FDA''''s critical path initiative.
The Collaborative Project on Mendelian Forms of Parkinson's Disease (MEFOPA) is a consortium that advances the basic and clinical research on rare Mendelian forms of Parkinson's disease (PD) by identifying and validating relevant disease-related molecular pathways, drug-targets and biomarkers for disease susceptibility and progression.
The Inflammatory Bowel Disease Biomarkers Consortium (IBD-BIOM) addresses the need to improve our understanding of inflammatory bowel disease (IBD) through new biomarkers into molecular dysfunctions that give rise to IBD. The biomarkers targeted by the consortium will be translated into early-detection clinical diagnostic tests for IBD patients.
The goal of the Imaging of Neuroinflammation in Neurodegenerative Diseases (INMiND) consortium is to identify novel biological targets of neuroinflammation for both diagnostic and therapeutic purposes, and to translate this knowledge into clinical application and patient benefit. The consortium supports collaborative research on molecular mechanisms that link neuroinflammation with neurodegeneration.
The Glycomics by High-throughput Integrated Technologies (GlycoHIT) consortium aims to advance the development of reliable and fast diagnostic tests for the early detection of cancer. By creating high-throughput technologies to analyze altered sugars, or glycobiomarkers, the consortium aims to allow scientists to diagnose different forms of cancer from a simple blood test without the need for biopsy. GlycoHIT will also further develop sugar testing technologies to allow this rapid form of diagnosis to be used in a clinical setting.
The Global Research in Paediatrics (GRiP) consortium focuses on the lack of appropriate testing of pediatric drugs. In particular, most pediatric medications having inadequate information about dosing regimen, dose adjustment and administration. GRiP partners are working to build and maintain an infrastructure matrix, which has the core aim of reducing the current fragmentation of the efforts to study and develop the use of medicine in children. By linking the existing pediatric research networks, GRIP will involve more than 1000 institutions worldwide.
The NeuroML database is a curated relational database that provides for the storage and retrieval of computational neuroscience models expressed in NeuroML, which is an extensible XML-based language for describing complex mathematical models of neurons and neuronal networks. NeuroML models are unique in their modular and multi-scale structure, where subcomponents of models can correspond to neuroscience models. In particular, the NeuroML database allows for efficient searches over the components of models and metadata that are associated with a hierarchical NeuroML model description.
The Genetic Association Information Network (GAIN) supports a series of Genome-Wide Association Studies (GWAS) designed to identify specific points of DNA variation associated with the occurrence of a particular common disease. Initially focusing on six major common diseases, GAIN focused on combining the results with clinical data to create a significant new resource for genetic researchers.
The Fatty Liver: Inhibition of Progression consortium (FLIP) aims to study the mechanisms of progression of liver disease in NAFLD to provide strategies for prevention and therapy. The project is based on the largest European cohort of patients with histologically diagnosed NAFLD, assembled with clinical and epidemiological data, and with biobanks of DNA, frozen liver tissue and serum. The consortium''s efforts span all the steps of the disease for studying cellular mechanisms of progression, with a goal of answering key issues dealing with the interplay of metabolic, inflammatory and fibrotic factors in the initiation and perpetuation of liver injury.
The European Network for Translational Research in Atrial Fibrillation (EUTRAF) consortium brings together investigators aiming to accelerate knowledge in the pathophysiology and treatment of Atrial Fibrillation. By integrating the mutually complementary strengths and expertise from molecular and cellular electrophysiology to the study of large cohort of patients, EUTRAF aims to develop approaches for increasing knowledge of the arrhythmogenic substrate, with the ultimate goal of developing novel treatments and diagnostic tools.
THIS RESOURCE IS NO LONGER IN SERVICE. Documented on June 9,2023. Registry that archives curated nanomaterial research data and their biological and environmental implications. The Registry provides data management plans for researchers, and accepts users' public-ready data, archive them, integrate them into the registry, allowing for the data to be shared publicly. Users can request more information on specific nanomaterial records, compare multiple nanomaterials, and export data to their desktop.
Immune tolerance data management and visualization portal for studies sponsored by Immune Tolerance Network (ITN) and collaborating investigators. Data from published studies are accessible to any user; data from current in-progress studies are accessible to study investigators and collaborators. Includes links to published Figures, tools for visualization and analysis of data, and ability to query study data by subject, group, or any other study parameter.
Central data repository that supplies organisms and reagents to the broad community of microbiology and infectious diseases researchers.
The European large-scale functional genomics in the rat for translational research (EURATRANS) consortium brings together investigators who will use next-generation sequencing technologies to generate genomic, transcriptomic and epigenomic datasets. The goal is to create quantitative metabonomic and proteomic datasets to give significant depth of coverage, at multiple levels, across pathophysiological phenotypes. The aim is to enable insights into disease mechanisms, through an integrative, cross-disciplinary approach to understanding large-scale functional genomic datasets in rats and humans.
The Markers for Sub-Clinical Cardiovascular Risk Assessment (EU-MASCARA) consortium aims to improve diagnosis of cardiovascular diseases and prediction of cardiovascular risk by analyzing a panel of biomarkers. EU-MASCARA aims to validate biomarkers that have been proposed to be associated with cardiovascular disease and risk across different disease entities and also in independent general population samples. The most robust biomarkers will be implemented in novel biochip based assays for clinical use.
The MicroRNAs in the Pathogenesis, Treatment and Prevention of Epilepsy (EpimiRNA) consortium aims to understand molecular mechanisms, diagnostics and develop novel therapeutics for epilepsy. The consortium aims to apply recent scientific breakthroughs that identified a new family of molecules that affect brain cell structure and function called microRNAs, to better understand medical products targeted to epilepsy.
The European Network for Genetic and Genomic Epidemiology (ENGAGE) consortium aims to translate data emerging from large-scale research efforts in molecular epidemiology into information of direct relevance to future advances in clinical medicine. The ENGAGE consortium will integrate and analyze one of the largest ever human genetics dataset (more than 80,000 genome-wide association scans and DNAs and serum/plasma samples from over 600,000 individuals). One goal is to demonstrate that the findings from ENGAGE can be used as diagnostic indicators for common diseases that will help us to understand better risk factors, disease progression and why people differ in responses to treatment.